Simon Laban

List of Publications by Year
in descending order

61	3,007	393982 19	182168 51
papers	citations	h-index	g-index

76	76	76	4204
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
2	Patterns of Tumor Infiltrating Lymphocytes in Adenoid Cystic Carcinoma of the Head and Neck. Cancers, 2022, 14, 1383.	1.7	5
3	Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response. Frontiers in Oncology, 2022, 12, 862694.	1.3	1
4	Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.. Journal of Clinical Oncology, 2022, 40, 6064-6064.	0.8	2
5	Immune checkpoint expression in <scp>HNSCC</scp> patients before and after definitive chemoradiotherapy. Head and Neck, 2021, 43, 778-787.	0.9	12
6	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). International Journal of Cancer, 2021, 148, 2023-2035.	2.3	6
7	Analysis, identification and visualization of subgroups in genomics. Briefings in Bioinformatics, 2021, 22, .	3.2	4
8	Increasing Mean Age of Head and Neck Cancer Patients at a German Tertiary Referral Center. Cancers, 2021, 13, 832.	1.7	13
9	Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 1335.	1.7	14
10	Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma. Frontiers in Medicine, 2021, 8, 640515.	1.2	13
11	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers, 2021, 13, 1959.	1.7	11
12	Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice. International Journal of Molecular Sciences, 2021, 22, 247.	1.8	14
13	Adenosine production in mesenchymal stromal cells in relation to their developmental status. Hno, 2020, 68, 87-93.	0.4	6
14	Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells. International Journal of Cancer, 2020, 147, 202-217.	2.3	15
15	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378.		51
16	Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC). BMC Cancer, 2020, 20, 701.	1.1	8
17	Circulating Exosomes Inhibit B Cell Proliferation and Activity. Cancers, 2020, 12, 2110.	1.7	19
18	Immune Suppressive Effects of Plasma-Derived Exosome Populations in Head and Neck Cancer. Cancers, 2020, 12, 1997.	1.7	27

#	Article	IF	Citations
19	Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5181.	1.8	17
20	HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells, 2020, 9, 2103.	1.8	48
21	Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5990.	1.8	14
22	NF-Î¹B and Its Role in Checkpoint Control. International Journal of Molecular Sciences, 2020, 21, 3949.	1.8	45
23	Adenosine-producing regulatory B cells in head and neck cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1205-1216.	2.0	24
24	Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma. Immunity and Ageing, 2020, 17, 3.	1.8	34
25	Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. Frontiers in Oncology, 2020, 10, 591063.	1.3	3
26	A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).. Journal of Clinical Oncology, 2020, 38, 6519-6519.	0.8	3
27	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 6551-6551.	0.8	1
28	Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells. Laryngo- Rhino- Otologie, 2020, 99, .	0.2	0
29	Receptor tyrosine kinase MET as potential target of multiâ€kinase inhibitor and radiosensitizer sorafenib in HNSCC. Head and Neck, 2019, 41, 208-215.	0.9	6
30	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. International Journal of Cancer, 2019, 145, 3436-3444.	2.3	8
31	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 1915-1928.	6.3	1,804
32	Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. Clinical Cancer Research, 2019, 25, 7405-7412.	3.2	13
33	Immunotherapy for head and neck cancers: an update and future perspectives. Immunotherapy, 2019, 11, 561-564.	1.0	4
34	Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. Immunotherapy, 2019, 11, 1193-1203.	1.0	3
35	Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).. Journal of Clinical Oncology, 2019, 37, TPS6093-TPS6093.	0.8	1
36	Polyfunctionality of CD4+ TÂlymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2018, 194, 392-402.	1.0	8

#	Article	IF	Citations
37	Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma. American Journal of Pathology, 2018, 188, 72-83.	1.9	22
38	Human Papillomavirus Immunity in Oropharyngeal Cancer: Time to Change the Game?. Clinical Cancer Research, 2018, 24, 505-507.	3.2	9
39	The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma. Oncotarget, 2018, 9, 5834-5847.	0.8	19
40	Response Evaluation in Head and Neck Oncology: Definition and Prediction. Orl, 2017, 79, 14-23.	0.6	7
41	Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer. Photodiagnosis and Photodynamic Therapy, 2017, 19, 194-201.	1.3	41
42	Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism. Cancer Research, 2017, 77, 1188-1199.	0.4	71
43	Novel Treatment Options in Head and Neck Cancer. Oncology Research and Treatment, 2017, 40, 342-346.	0.8	9
44	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	0.8	21
45	Curative treatment of head and neck squamous cell carcinoma. Hno, 2016, 64, 501-507.	0.4	6
46	Clinical characteristics and outcomes of oropharyngeal carcinoma related to highâ€risk nonâ€“human papillomavirus16 viral subtypes. Head and Neck, 2016, 38, 1330-1337.	0.9	33
47	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head and Neck, 2016, 38, 1008-1016.	0.9	14
48	Evaluation of Customized Prosthesis for Irregularly Formed Tracheostoma After Laryngectomy. Annals of Otology, Rhinology and Laryngology, 2016, 125, 145-150.	0.6	8
49	Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget, 2016, 7, 23542-23551.	0.8	18
50	Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 42988-42995.	0.8	64
51	Abstract B142: Immunoprofiling head and neck cancer: Preliminary data of the IRECT trial (Immune) Tj ETQq1 1 0.784314 rgBT /Overl		0
52	Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Research, 2015, 25, 503-509.	0.6	59
53	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiotherapy and Oncology, 2015, 115, 120-127.	0.3	47
54	Abstract B50: The influence of chemotherapy on adenosine-producing B cells in patients with head and neck cancer. , 2015, , .		0

#	Article	IF	Citations
55	Simultaneous cytoplasmic and nuclear protein expression of melanoma antigenâ€A family and NYâ€ESOâ€1 cancerâ€testis antigens represents an independent marker for poor survival in head and neck cancer. International Journal of Cancer, 2014, 135, 1142-1152.	2.3	46
56	Molecular targeting agents in the context of primary chemoradiation strategies. Head and Neck, 2013, 35, 738-746.	0.9	4
57	HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1. Radiotherapy and Oncology, 2013, 108, 495-499.	0.3	39
58	Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiotherapy and Oncology, 2013, 109, 286-292.	0.3	37
59	11q21 Rearrangement is a Frequent and Highly Specific Genetic Alteration in Mucoepidermoid Carcinoma. Diagnostic Molecular Pathology, 2012, 21, 134-137.	2.1	52
60	Cytotoxic natural antibodies against human tumours: An option for anti-cancer immunotherapy?. Autoimmunity Reviews, 2008, 7, 491-495.	2.5	35
61	Cargo and Functional Profile of Saliva-Derived Exosomes Reveal Biomarkers Specific for Head and Neck Cancer. Frontiers in Medicine, 0, 9, .	1.2	9